A new study issued by the Boston University School of Medicine revealed the development of a new and potentially safe therapeutic tool to restore liver function in chronic and acute liver diseases, represented by the mRNA-LNP DNA code, according to MedicalXpress.
Valerie John Evans, one of the researchers in the study, said that rapid intervention using that genetic code could restore liver function, stressing that the safety of mRNA-LNP has been verified in clinical trials of applications such as cancer immunotherapy and recently the first coronavirus vaccines approved by Pfizer. And our moderna.
The researchers used two experimental models in which the liver was injured, where the first group was injected with mRNA-LNP, which produces liver methogens, and then the second group was injected with an RNA-LNP antagonist that does not produce any protein, which led to the restoration of liver function again.
The study indicated that there are no FDA approved drugs for treating chronic liver disease, and new strategies are urgently needed to prevent the progression of liver disease before it reaches the stage of decompensated cirrhosis and steatosis (accumulation of fat in liver cells). It is one of the first stages of liver disease development.
Notably, with the experimental results, the researchers hope that methogene delivery can be translated using mRNA-LNP, to prevent the development of chronic liver disease and even restore some features of nonalcoholic fatty liver disease.
Comments
Post a Comment